Chronic pharmacologic inhibition of EGFR leads to cardiac dysfunction in C57BL/6J mice.

No abstract is available for this paper.

• Publication year

  2008

• Venue

  Toxicology and Applied Pharmacology

• Publication date

  2008-05-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1016/j.taap.2007.12.012PMID 18313710PMCID PMC2683406
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Phase I dose-finding and pharmacokinetic study of the oral epidermal growth factor receptor tyrosine kinase inhibitor Ro50-8231 (erlotinib) in Japanese patients with solid tumors

  2008cited by this paper
• Small Molecule Tyrosine Kinase Inhibitors in the Treatment of Solid Tumors: An Update of Recent Developments

  2007cited by this paper
• Chronic pain in the cancer survivor: a new frontier.

  2007cited by this paper
• Clinical implications of the mechanism of epidermal growth factor receptor inhibitors

  2006cited by this paper
• Is there a role for the irreversible epidermal growth factor receptor inhibitor EKB-569 in the treatment of cancer? A mutation-driven question.

  2006cited by this paper
• An Angiotensin II Type 1 Receptor Mutant Lacking Epidermal Growth Factor Receptor Transactivation Does Not Induce Angiotensin II–Mediated Cardiac Hypertrophy

  2006cited by this paper
• Preclinical analysis of the analinoquinazoline AG1478, a specific small molecule inhibitor of EGF receptor tyrosine kinase.

  2006influential reference
• Pharmacogenomics of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors.

  2006influential reference
• Viewing ovarian cancer as a "chronic disease": what exactly does this mean?

  2006cited by this paper
• Galphaq expression activates EGFR and induces Akt mediated cardiomyocyte survival: dissociation from Galphaq mediated hypertrophy.

  2006cited by this paper
• Tackling the EGFR in pathological tissue remodelling.

  2006cited by this paper
• A high fat/high carbohydrate diet induces aortic valve disease in C57BL/6J mice.

  2006cited by this paper
• Neuregulin-1/erbB-activation improves cardiac function and survival in models of ischemic, dilated, and viral cardiomyopathy.

  2006cited by this paper
• Gαq expression activates EGFR and induces Akt mediated cardiomyocyte survival: dissociation from Gαq mediated hypertrophy

  2006cited by this paper
• Gefitinib: an adverse effects profile

  2006cited by this paper
• Interstitial lung disease associated with epidermal growth factor receptor tyrosine kinase inhibitor therapy in non-small-cell lung carcinoma.

  2006cited by this paper
• Effect of Dominant-Negative Epidermal Growth Factor Receptors on Cardiomyocyte Hypertrophy

  2006cited by this paper
• Phase I study of EKB-569, an irreversible inhibitor of the epidermal growth factor receptor, in patients with advanced solid tumors.

  2006cited by this paper
• Neuregulin receptors erbB2 and erbB4 in failing human myocardium

  2005cited by this paper
• Modern management of recurrent ovarian carcinoma. A systematic approach to a chronic disease.

  2005cited by this paper
• Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib.

  2005cited by this paper
• Dilated cardiomyopathy in Erb-b4-deficient ventricular muscle.

  2005cited by this paper
• Inhibition of ErbB2 causes mitochondrial dysfunction in cardiomyocytes: implications for herceptin-induced cardiomyopathy.

  2004cited by this paper
• Recent increase in cancer survival according to age: higher survival in all age groups, but widening age gradient

  2004cited by this paper
• Modeling the cancer patient with genetically engineered mice: prediction of toxicity from molecule-targeted therapies.

  2004cited by this paper
• Essential roles of Her2/erbB2 in cardiac development and function.

  2004cited by this paper
• Activated epidermal growth factor receptor (ErbB1) protects the heart against stress-induced injury in mice.

  2003cited by this paper
• Inhibition of zebrafish epidermal growth factor receptor activity results in cardiovascular defects.

  2003cited by this paper
• Future directions in the management of ovarian cancer.

  2003cited by this paper
• Heparin-binding EGF-like growth factor and ErbB signaling is essential for heart function

  2003cited by this paper
• Defective valvulogenesis in HB‐EGF and TACE‐null mice is associated with aberrant BMP signaling

  2003cited by this paper
• Fatal pulmonary toxicity in a patient treated with gefitinib for non-small cell lung cancer after previous hemolytic-uremic syndrome due to gemcitabine.

  2003cited by this paper
• Analysis of HER2 and HER4 in Human Myocardium to Clarify the Cardiotoxicity of Trastuzumab (Herceptin™)

  2003cited by this paper
• Neuregulin-1 protects ventricular myocytes from anthracycline-induced apoptosis via erbB4-dependent activation of PI3-kinase/Akt.

  2003cited by this paper
• Synthesis and Structure−Activity Relationships of 6,7-Disubstituted 4-Anilinoquinoline-3-carbonitriles. The Design of an Orally Active, Irreversible Inhibitor of the Tyrosine Kinase Activity of the Epidermal Growth Factor Receptor (EGFR) and the Human Epidermal Growth Factor Receptor-2 (HER-2)

  2003influential reference
• Left ventricular unloading alters receptor tyrosine kinase expression in the failing human heart.

  2002cited by this paper
• ErbB2 is essential in the prevention of dilated cardiomyopathy

  2002cited by this paper
• Conditional mutation of the ErbB2 (HER2) receptor in cardiomyocytes leads to dilated cardiomyopathy

  2002cited by this paper
• Importance of epidermal growth factor receptor signaling in establishment of adenomas and maintenance of carcinomas during intestinal tumorigenesis

  2002cited by this paper
• Trastuzumab cardiotoxicity: Speculations regarding pathophysiology and targets for further study.

  2002influential reference
• Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method.

  2001cited by this paper
• The epidermal growth factor receptor: from mutant oncogene in nonhuman cancers to therapeutic target in human neoplasia.

  2001cited by this paper
• Cardiotoxicity in signal transduction therapeutics: erbB2 antibodies and the heart.

  2001cited by this paper
• EGFR and cancer prognosis.

  2001cited by this paper
• EGFR tyrosine kinase inhibitor AG1478 inhibits cell proliferation and arrests cell cycle in nasopharyngeal carcinoma cells.

  2001cited by this paper
• Cell signaling by receptor tyrosine kinases.

  2000cited by this paper
• Salivary epidermal growth factor and intestinal adaptation in male and female mice.

  2000cited by this paper
• Blockade of the epidermal growth factor receptor tyrosine kinase suppresses tumorigenesis in MMTV/Neu + MMTV/TGF-alpha bigenic mice.

  2000cited by this paper
• Combinatorial chemoprevention of intestinal neoplasia

  2000influential reference
• Mice mutant for Egfr and Shp2 have defective cardiac semilunar valvulogenesis

  2000cited by this paper
• Cell signaling by receptor tyrosine kinases.

  2000cited by this paper
• The epidermal growth factor receptor and its inhibition in cancer therapy.

  1999cited by this paper
• Neuregulin signaling in the heart. Dynamic targeting of erbB4 to caveolar microdomains in cardiac myocytes.

  1999cited by this paper
• EGF receptor.

  1999influential reference
• Cardiotoxicity in patients receiving transtuzumab (Herceptin): primary toxicity, synergistic or sequential stress, or surveillance artifact?

  1999cited by this paper
• Inhibition of epidermal-growth-factor-receptor-dependent signalling by tyrphostins A25 and AG1478 blocks growth and induces apoptosis in colorectal tumor cells in vitro

  1999cited by this paper
• Therapy of metastatic breast cancer with humanized antibodies against the HER2 receptor protein

  1999influential reference
• Neuregulin in cardiac hypertrophy in rats with aortic stenosis. Differential expression of erbB2 and erbB4 receptors.

  1999cited by this paper
• Expression of the c‐erbB‐4/HER4 protein and mRNA in normal human fetal and adult tissues and in a survey of nine solid tumour types

  1998cited by this paper
• TGF-beta signal transduction.

  1998cited by this paper
• Neuregulins Promote Survival and Growth of Cardiac Myocytes

  1998influential reference
• ErbB3 is required for normal cerebellar and cardiac development: a comparison with ErbB2-and heregulin-deficient mice.

  1997cited by this paper
• Epidermal growth factor-related peptides and their receptors in human malignancies.

  1995cited by this paper
• Tyrosine kinase inhibition: an approach to drug development.

  1995cited by this paper
• Tyrosine kinase inhibition: an approach to drug development.

  1995influential reference
• Aberrant neural and cardiac development in mice lacking the ErbB4 neuregulin receptor

  1995cited by this paper
• Requirement for neuregulin receptor erbB2 in neural and cardiac development

  1995cited by this paper
• Genetic identification of Mom-1, a major modifier locus affecting Min-induced intestinal neoplasia in the mouse.

  1993cited by this paper
• Histotechnology. A self‐instructional text

  1992cited by this paper
• Regional distribution and developmental expression of epidermal growth factor and transforming growth factor-alpha mRNA in mouse brain by a quantitative nuclease protection assay

  1992cited by this paper
• Histotechnology: A Self-Instructional Text

  1990cited by this paper
• Similarity of protein encoded by the human c-erb-B-2 gene to epidermal growth factor receptor

  1986cited by this paper
• Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene.

  1985cited by this paper
• Monoclonal anti-epidermal growth factor receptor antibodies which are inhibitors of epidermal growth factor binding and antagonists of epidermal growth factor binding and antagonists of epidermal growth factor-stimulated tyrosine protein kinase activity.

  1984cited by this paper
• Growth inhibition of human tumor cells in athymic mice by anti-epidermal growth factor receptor monoclonal antibodies.

  1984cited by this paper
• Biological effects in vitro of monoclonal antibodies to human epidermal growth factor receptors.

  1983cited by this paper

• Systematic analysis of doxorubicin-induced myocardial injury mechanisms using network toxicology and molecular docking strategy

  2025cites this paper
• Major adverse cardiovascular events in advanced-stage lung cancer: a multicenter cohort study

  2024cites this paper
• The role of EGFR in vascular AT1R signaling: From cellular mechanisms to systemic relevance.

  2023cites this paper
• Decoding of miR-7-5p in Colony Forming Unit–Hill Colonies as a Biomarker of Subclinical Cardiovascular Disease—A MERIT Study

  2023cites this paper
• Cardiovascular toxicity of tyrosine kinase inhibitors during cancer treatment: Potential involvement of TRPM7

  2023influential citation
• Cardiac pericyte reprogramming by MEK inhibition promotes arteriologenesis and angiogenesis of the ischemic heart

  2022cites this paper
• Prioritizing Candidate Genes for Type 2 Diabetes Mellitus using Integrated Network and Pathway Analysis

  2022cites this paper
• GPCR-ErbB transactivation pathways and clinical implications.

  2021cites this paper
• The Role of Epidermal Growth Factor Receptor Family of Receptor Tyrosine Kinases in Mediating Diabetes-Induced Cardiovascular Complications

  2021cites this paper
• Epidermal growth factor receptor-dependent maintenance of cardiac contractility.

  2021cites this paper
• Contractile reprogramming of cardiac pericytes by MEK inhibition promotes arteriologenesis of the ischemic heart

  2020cites this paper
• The heart of a hibernator: EGFR and MAPK signaling in cardiac muscle during the hibernation of thirteen-lined ground squirrels, Ictidomys tridecemlineatus

  2019cites this paper
• EGFR tyrosine kinase inhibition decreases cardiac remodeling and SERCA2a/NCX1 depletion in streptozotocin induced cardiomyopathy in C57/BL6 mice

  2018cites this paper
• Novel role for cardiac myocyte-derived β-2 microglobulin in mediating cardiac fibrosis.

  2018cites this paper
• Cardiac GPCR–Mediated EGFR Transactivation: Impact and Therapeutic Implications

  2017cites this paper
• Transactivation of the epidermal growth factor receptor in responses to myocardial stress and cardioprotection.

  2017cites this paper
• Approved and Experimental Small‐Molecule Oncology Kinase Inhibitor Drugs: A Mid‐2016 Overview

  2017cites this paper
• EGFR transactivation: mechanisms, pathophysiology and potential therapies in cardiovascular system

  2017cites this paper
• High throughput screening of kinase inhibitor drugs on cardiac function using engineered heart tissue constructs

  2017cites this paper
• Epidermal Growth Factor Receptor Transactivation: Mechanisms, Pathophysiology, and Potential Therapies in the Cardiovascular System.

  2016cites this paper
• ROLE OF EPIDERMAL GROWTH FACTOR RECEPTOR ON CARDIAC FUNCTION

  2015cites this paper
• Diabetic cardiomyopathy: Role of epidermal growth factor receptor tyrosine kinase.

  2015cites this paper
• Temporal and gefitinib-sensitive regulation of cardiac cytokine expression via chronic β-adrenergic receptor stimulation.

  2015cites this paper
• Moderate inappropriately high aldosterone/NaCl constellation in mice: cardiovascular effects and the role of cardiovascular epidermal growth factor receptor

  2014cites this paper
• The role of epidermal growth factor receptor in diabetes-induced cardiac dysfunction.

  2013cites this paper
• CB1 cannabinoid receptor deficiency promotes cardiac remodeling induced by pressure overload in mice.

  2013cites this paper
• The Epidermal Growth Factor Receptor Is Involved in Angiotensin II But Not Aldosterone/Salt-Induced Cardiac Remodelling

  2012cites this paper
• The EGFR tyrosine kinase inhibitor tyrphostin AG-1478 causes hypomagnesemia and cardiac dysfunction.

  2012cites this paper
• Activation of EGFR/ERBB2 via Pathways Involving ERK1/2, P38 MAPK, AKT and FOXO Enhances Recovery of Diabetic Hearts from Ischemia-Reperfusion Injury

  2012cites this paper
• Involvement of Depressive Catecholamines as Thrombosis Risk/Inflammatory Markers in Non-Smoker, Non-Obese Congestive Heart Failure, Linked to Increased Epidermal Growth Factor-Receptor (EGF-R) Production

  2011cites this paper
• Suppressor of cytokine signaling-2 (SOCS2) and epidermal growth factor (EGF) modulate insulin-like growth factor-I receptor (IGF-IR) signaling in intestinal cancer

  2010cites this paper
• Epidermal growth factor protects the heart against low-flow ischemia-induced injury

  2010cites this paper
• The vulnerability of the heart as a pluricellular paracrine organ: lessons from unexpected triggers of heart failure in targeted ErbB2 anticancer therapy.

  2010cites this paper
• ErbB receptors protect the perfused heart against injury induced by epinephrine combined with low-flow ischemia

  2009cites this paper
• Epidermal growth factor receptor gene polymorphisms, R497K, but not (CA)n repeat, is associated with dilated cardiomyopathy.

  2009cites this paper
• The Role of Neuregulin 1 β /ErbB signaling in the heart

  2009cites this paper
• Acute and chronic adrenergic stimulation of submandibular salivary glands. Effects on the endocrine function of epidermal growth factor in mice

  2009cites this paper
• The role of Neuregulin-1beta/ErbB signaling in the heart.

  2009cites this paper
• Reduced EGFR causes abnormal valvular differentiation leading to calcific aortic stenosis and left ventricular hypertrophy in C57BL/6J but not 129S1/SvImJ mice.

  2009cites this paper